“Wolverine” is a combination product, not a single molecule. It pairs two synthetic research peptides — BPC-157, a 15-amino-acid sequence derived from a fragment of human gastric juice protein, and TB-500, an acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin β4. Each peptide has its own separate preclinical literature centred on tissue repair, angiogenesis, and cell migration. The blend itself has been studied very little: the rationale for combining them is theoretical, drawn from the individual component data below, not from trials of the mixture. For research use only (RUO). Neither component is an approved drug in Canada or elsewhere.
Sequence & identity
This is a two-component blend, so there is no single sequence. BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (pentadecapeptide, 15 residues). TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (N-acetylated heptapeptide, residues 17–23 of thymosin β4).
Structure shown is conceptual: Wolverine is a physical mixture of two distinct peptide molecules, not a single conjugated compound. There is no combined molecular formula, molecular weight, or CAS number — each peptide retains its own identity in solution.
Mechanisms studied
BPC-157. In animal and cell-culture models, researchers reported that BPC-157 upregulates the VEGFR2 receptor and signals through the Akt–endothelial nitric oxide synthase (eNOS) pathway, increasing nitric oxide production and promoting angiogenesis (new blood-vessel formation) at injury sites.1,5 In cultured tendon fibroblasts, studies observed increased phosphorylation of focal adhesion kinase (FAK) and paxillin, associated with greater cell migration and survival.6 These are mechanistic observations in non-human systems; they are not established human effects.
TB-500. TB-500 corresponds to the actin-binding domain of thymosin β4. The parent protein binds monomeric G-actin in a roughly 1:1 ratio and sequesters it, regulating actin polymerisation and thereby cell migration.2,7 In endothelial-cell studies, thymosin β4 was reported to act as a chemoattractant and to promote angiogenesis, in part by upregulating VEGF expression.7 How much of this activity the isolated Ac-LKKTETQ fragment reproduces is not fully established.
Combination rationale. The two peptides are paired on the theory that they act on overlapping repair pathways (angiogenesis and cell migration) by different mechanisms. This combined mechanism has not been directly demonstrated for the blend in published controlled studies — it is an inference from the separate component literature.
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| BPC-157 preclinical (rat tendon/ligament and GI models) | Component study parameter, not a blend instruction. Animal studies commonly applied roughly 10 µg/kg to 10 ng/kg body weight via intraperitoneal, intragastric, or local routes. | These are dosing parameters used in non-human studies of BPC-157 alone. No validated human dose exists; values do not transfer to people and are not directions for use. |
| TB-500 / thymosin β4 fragment preclinical | Component study parameter, not a blend instruction. Animal repair models have used thymosin β4 / Ac-LKKTETQ in the microgram-per-animal to milligram-per-kilogram range depending on model and route. | These are study conditions for the single peptide in animals. No established human dose; not a directive for human administration. |
| The Wolverine blend specifically | No validated regimen. There are no published clinical dosing studies of the BPC-157 + TB-500 combination. | Any ratio or amount circulated for the blend is unverified and not supported by controlled data. Research use only. |
Effects observed in research
For the components individually, preclinical (animal and in-vitro) studies reported associations with accelerated tendon and ligament healing, gastrointestinal mucosal protection, and tissue repair for BPC-157,1,3 and with cell migration, angiogenesis, and wound-healing processes for thymosin β4 / TB-500.2,7 Human evidence is very limited for both: BPC-157 has only a small amount of preliminary human data and no completed efficacy trials,1 and TB-500 has no established human efficacy data.2 For the blend specifically, no peptide combination outcome has been demonstrated in controlled human or animal studies. Reported effects are not approved indications and do not constitute medical claims.
Strength of evidence
Honest grade: C. The component-level literature is largely animal and in-vitro, with only sparse preliminary human data for BPC-157 and essentially none for TB-500. Critically, the combination itself has little to no direct published study — the case for stacking the two is theoretical, assembled from separate single-peptide reports rather than head-to-head or combination trials. Neither BPC-157 nor TB-500 is approved by any drug regulatory agency for human use; both are prohibited in sport by the World Anti-Doping Agency (BPC-157 since 2022). Where data is absent, the honest statement is “not established.”
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- Wikipedia. BPC-157. https://en.wikipedia.org/wiki/BPC-157
- Wikipedia. TB-500. https://en.wikipedia.org/wiki/TB-500
- PubChem. BPC-157, CID 9941957. https://pubchem.ncbi.nlm.nih.gov/compound/9941957
- PubChem / MedKoo. TB-500 (synthetic thymosin β4 fragment), CAS 885340-08-9. https://www.medkoo.com/products/41195
- Hsieh M-J, et al. Pro-angiogenic effects of BPC-157 via VEGFR2 and Akt-eNOS signalling (preclinical). PubMed. https://pubmed.ncbi.nlm.nih.gov/
- Chang C-H, et al. Pentadecapeptide BPC-157 enhances tendon fibroblast outgrowth, migration and survival (FAK/paxillin). PMC6271067. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271067/
- Malinda KM, et al. Thymosin β4 stimulates directional migration of endothelial cells and promotes angiogenesis. PubMed 9194528. https://pubmed.ncbi.nlm.nih.gov/9194528/